945976-43-2

Basic information

• Product Name: LP 533401
• Synonyms: LP 533401;LP-533401 /L-Phenylalanine, 4-[2-amino-6-[2,2,2-trifluoro-1-(3'-fluoro[1,1'-biphenyl]-4-yl)ethoxy]-4-pyrimidinyl]-;L-Phenylalanine, 4-[2-amino-6-[2,2,2-trifluoro-1-(3\'-fluoro[1,1\'-biphenyl]-4-yl)ethoxy]-4-pyrimidinyl]-
• CAS NO: 945976-43-2
• Molecular Formula: C27H22F4N4O3
• Molecular Weight: 526.4821928
• Mol File: 945976-43-2.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 699.0±65.0 °C(Predicted)
• Appearance: /
• Density: 1.388±0.06 g/cm3(Predicted)
• PKA: 2.04±0.10(Predicted)
• CAS DataBase Reference: LP 533401(CAS DataBase Reference)
• NIST Chemistry Reference: LP 533401(945976-43-2)
• EPA Substance Registry System: LP 533401(945976-43-2)

Safety Data

• Hazardous Substances Data: 945976-43-2(Hazardous Substances Data)

Usage

Description

LP 533401 is a compound that inhibits tryptophan hydroxylase 1 (Tph1), which is the rate-limiting enzyme responsible for serotonin production.

Uses

Used in Pharmaceutical Industry:
LP 533401 is used as a pharmaceutical agent for the treatment of conditions related to serotonin dysregulation. By inhibiting Tph1, it can help regulate serotonin levels in the body, potentially providing therapeutic benefits for various disorders.
Used in Research Applications:
LP 533401 is used as a research tool for studying the role of serotonin in various biological processes and disorders. Its ability to inhibit Tph1 makes it a valuable compound for investigating the mechanisms underlying serotonin production and its impact on physiological and pathological conditions.

Upstream product

• 945978-64-3 4-chloro-6-(2,2,2-trifluoro-1-(3'-fluoro-[1,1'-biphenyl]-4-yl)ethoxy)pyrimidin-2-amine 
• 76410-58-7 p-borono-L-phenylalanine 

Relevant articles and documents

Modulation of peripheral serotonin levels by novel tryptophan hydroxylase inhibitors for the potential treatment of functional gastrointestinal disorders

The discovery of a novel class of peripheral tryptophan hydroxylase (TPH) inhibitors is described. This class of TPH inhibitors exhibits excellent potency in in vitro biochemical and cell-based assays, and it selectively reduces serotonin levels in the murine intestine after oral administration without affecting levels in the brain. These TPH1 inhibitors may provide novel treatments for gastrointestinal disorders associated with dysregulation of the serotonergic system, such as chemotherapy-induced emesis and irritable bowel syndrome.